跳转至内容
Merck
CN

32097

Supelco

依托考昔

VETRANAL®, analytical standard

别名:

5-氯-3-[4-(甲磺酰基)苯基]-2-(2-甲基-5-吡啶基)吡啶, 5-氯-6′-甲基-3-[4-(甲磺酰基)苯基]]-2,3′-联吡啶

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C18H15ClN2O2S
分子量:
358.84
Beilstein:
8073797
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24

等级

analytical standard

质量水平

产品线

VETRANAL®

保质期

limited shelf life, expiry date on the label

技术

HPLC: suitable
gas chromatography (GC): suitable

应用

forensics and toxicology
pharmaceutical (small molecule)
veterinary

格式

neat

储存温度

2-8°C

SMILES字符串

Cc1ccc(cn1)-c2ncc(Cl)cc2-c3ccc(cc3)S(C)(=O)=O

InChI

1S/C18H15ClN2O2S/c1-12-3-4-14(10-20-12)18-17(9-15(19)11-21-18)13-5-7-16(8-6-13)24(2,22)23/h3-11H,1-2H3

InChI key

MNJVRJDLRVPLFE-UHFFFAOYSA-N

基因信息

human ... PTGS2(5743)

正在寻找类似产品? 访问 产品对比指南

相关类别

一般描述

依托考昔是一种非甾体类环加氧酶-2(COX-2)选择性抗炎药,主要用于骨关节炎和类风湿性关节炎患者的治疗。

应用

依托考昔已被用作参考标准品,用于通过液相色谱-串联质谱-常压化学电离分析法(LC-APCI/MS/MS)检测人血浆中的依托考昔。
有关合适仪器技术的更多信息,请参考产品′s分析证书。如需进一步支持,请联系技术服务。

法律信息

VETRANAL is a registered trademark of Merck KGaA, Darmstadt, Germany

象形图

Skull and crossbones

警示用语:

Danger

危险声明

危险分类

Acute Tox. 2 Dermal - Acute Tox. 4 Oral

WGK

WGK 3


Choose from one of the most recent versions:

分析证书(COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Paola Patrignani et al.
Expert opinion on pharmacotherapy, 4(2), 265-284 (2003-02-04)
The development of COX2 inhibitors with improved biochemical selectivity (such as etoricoxib and valdecoxib) over that of commercially available coxibs has been driven by the potential advantage of safety using higher coxib doses for increased efficacy. Etoricoxib has been approved
Rik J Lories
Expert opinion on drug metabolism & toxicology, 8(12), 1599-1608 (2012-11-07)
Nonsteroidal anti-inflammatory drugs (NSAIDs) are first-line therapies in the management of patients with ankylosing spondylitis. This chronic inflammatory skeletal disorder, a subtype of spondyloarthritis, is characterized by inflammatory back pain and affects young adults causing important suffering and disability. Long-term
Rachel Clarke et al.
The Cochrane database of systematic reviews, (2)(2), CD004309-CD004309 (2009-04-17)
Etoricoxib is a selective cyclo-oxygenase-2 (COX-2) inhibitor prescribed for the relief of chronic pain in osteoarthritis and rheumatoid arthritis, and acute pain. The drug is believed to be associated with fewer upper gastrointestinal adverse effects than conventional non-steroidal anti-inflammatory drugs
Eugene R Viscusi et al.
Current medical research and opinion, 28(8), 1323-1335 (2012-06-29)
To evaluate the effects of two different doses of etoricoxib delivered perioperatively compared with placebo and standard pain management on pain at rest, pain with mobilization, and use of additional morphine/opioids postoperatively. In this double-blind, placebo-controlled, randomized clinical trial, we
Rachel Clarke et al.
The Cochrane database of systematic reviews, 4(4), CD004309-CD004309 (2012-04-20)
Etoricoxib is a selective cyclo-oxygenase-2 (COX-2) inhibitor licensed for the relief of chronic pain in osteoarthritis and rheumatoid arthritis, and acute pain in some jurisdictions. This class of drugs is believed to be associated with fewer upper gastrointestinal adverse effects

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门